Cronos Group: Canaccord Reiterates Sell Rating Follow Q4 2021 Results

Yesterday, Cronos Group (TSX: CRON) reported their fourth-quarter and full-year financial results. The company reported revenues of $25.8 million for the quarter, of which $18.8 million came from cannabis flower revenue, $3.8 million came from extracts, and $3.1 million came from their US based CBD business. The company saw its gross margins come in at 8%, and an adjusted EBITDA of ($27.4) million for the quarter.

For the year end, the company reported full year revenues of $74.4 million, up 59% year over year. Of that $74.4 million, $55.2 million came from cannabis flower, $8.8 million from extracts, and $9.8 million from their CBD business. The company reported full-year gross margins of (24%) and an adjusted EBITDA of ($160.5) million.

Cronos currently has 12 analysts covering the stock with an average 12-month price target of C$6.39, which represents a 46% upside to the current stock price. Out of the 12 analysts, 2 have buy ratings, 8 have hold ratings, 1 analyst has a sell rating and another analyst has a strong sell rating on Cronos’ stock. The street high sits at C$12, which represents a 175% upside to the stock price.

PTX Metals Inc. — sponsored Sponsored · PTX Metals Inc.

In Canaccord’s fourth quarter review note, they reiterate their sell rating on the name and C$4.25 12-month price target, saying that the earnings somewhat surprised them with better than expected numbers. Though they say that the numbers got overshadowed by a material impairment of its legacy Peace Naturals production and cultivate site.

On the quarterly results, Canaccord was forecasting that revenue would be $23.5 million with a gross margin of $941 thousand. This minor beat comes as Cronos’ CBD business is seeing a rebound in sales from the previous quarter but still below last year’s sales. The company also reported another quarter of better than expected sequential cannabis sales, with the company seeing its cannabis revenue grow by 24% quarter over quarter. Canaccord now believes that Cronos has a sub 5% market share in branded adult-use cannabis sales.

Cronos also notably reported its first positive gross margin percentage in over two years, with the company continuing to right-size its operations. Canaccord believes that the company is turning a new leaf. The biggest thing to note from the company’s income statement is the larger $120 million impairment on its Peace Naturals production and cultivation facility. This comes after it reported a $236 million impairment last quarter.

Below you can see Canaccord’s updated fiscal full year 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Is Agnico Eagle Seabridge Gold’s Mystery Lender?

This Gold Giant Is Building 1.5 Million More Ounces a Year | Agnico Eagle Q3 Earnings

This Gold Giant Was a Mess. Now It’s Back! | Barrick Mining Q3 2026 Earnings

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Cronos Pays OSC $1.3 Million As Penalty For Accounting Fraud, Settles SEC Charges

A Capital Markets Tribunal panel yesterday accepted a settlement agreement between the Ontario Securities Commission...

Tuesday, October 25, 2022, 11:01:00 AM

Vireo Health: Canaccord Lowers Revenue Estimates, Reiterates Price Target

Vireo Health (CSE: VREO) reported its second-quarter financials’ on August 26th, indicating revenue for the...

Thursday, August 27, 2020, 05:30:27 PM

SSR Mining: Canaccord Reiterates $35 Price Target, Buy Rating

Yesterday, SSR Mining (TSX: SSRM) reported its third quarter results. SSR Mining reported revenue of...

Friday, November 13, 2020, 02:32:00 PM

Canaccord Upgrades Valens Company Price Target Following US Entrance

The Valens Company (TSX: VLNS) was very busy over the course of the last week....

Sunday, May 2, 2021, 11:44:00 AM

Verano Holdings: Analysts Expect $122 Million In EBITDA For Q2

Verano Holdings (CSE: VRNO) announced that they will be reporting their second quarter financials before...

Sunday, August 8, 2021, 05:10:00 PM